Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 6/20 | 0.61 |
| ▸ | PPARD | Q03181 | 5/20 | 0.61 |
| ▸ | PPARA | Q07869 | 5/20 | 0.61 |
| ▸ | F7 | P08709 | 4/20 | 0.61 |
| ▸ | F3 | P13726 | 4/20 | 0.61 |
| ▸ | TERT | O14746 | 3/20 | 0.61 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.61 |
| ▸ | FABP4 | P15090 | 3/20 | 0.61 |
| ▸ | TOP1 | P11387 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | BLM | P54132 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.61 |
| ▸ | DUSP3 | P51452 | 2/20 | 0.61 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.61 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.61 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.61 |
| ▸ | PTPN7 | P35236 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31690251 | 1.00 | PPARG (0.61) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL4638677 | 1.00 | PPARG (0.61) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL31690250 | 1.00 | PPARG (0.61) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL17963056 | 1.00 | PPARG (0.61) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL2541979 | 1.00 | PPARG (0.61) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL31023483 | 1.00 | PPARG (0.61) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL3883978 | 1.00 | PPARG (0.61) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL11801299 | 1.00 | PPARG (0.61) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL847211 | 1.00 | PPARG (0.61) | PPARGPPARDPPARAF7F3 | |
| Pentadecane SCHEMBL28866305 | 1.00 | PPARG (0.61) | PPARGPPARDPPARAF7F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220249351-A1 | COSMETIC | NOEVIR CO., LTD. (JP) | 2022-08-11 | — | — | US | claimed |
| CN-113924081-A | Cosmetic preparation | 株式会社诺薇雅 | 2022-01-11 | — | — | CN | claimed |
| WO-2019058338-A1 | METHODS TO PRODUCE LIQUID OXYGEN EMULSION AND ADMINISTER INTRAVASCULAR LIQUID OXYGEN | AODH LIFESCIENCES PRIVATE LIMITED (IN) | 2019-03-28 | — | — | WO | claimed |
| EP-3251657-A1 | TOPICAL AQUEOUS SPRAY COMPOSITIONS OF HALOBETASOL | Sun Pharmaceutical Industries Limited (IN) | 2017-12-06 | — | — | EP | claimed |
| US-20170340649-A1 | TOPICAL AQUEOUS SPRAY COMPOSITIONS OF HALOBETASOL | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2017-11-30 | — | — | US | claimed |
| EP-1900353-A1 | Composition to combat localised hyperpigmentation in dark skin types | L'OREAL (FR) | 2008-03-19 | — | — | EP | claimed |
| EP-1129694-B1 | Use of components for modifying the physico-chemical properties of the skin and/or the mucous membrane as agents for preventing or reducing the adhesion of micro-organisms thereon | OREAL (FR) | 2005-09-07 | — | — | EP | claimed |
| US-20040047885-A1 | Use of compounds which make it possible to modify the physicochemical properties of the skin and/or the mucous membranes as agents preventing or reducing the adhesion of microorganisms to the latter | L'OREAL | 2004-03-11 | — | — | US | claimed |
| US-6461625-B1 | OIL IN WATER NANOEMULSION HAVING OIL GLOBULES WITH SPECIFIED SIZE, SURFACTANT SELECTED FROM ALKOXYLATED ALKENYL SUCCINATES OR ALKOXYLATED ALKENYL SUCCINATES OF GLUCOSE OR METHYLGLUCOSE, OIL HAVING SPECIFIED MOLECULAR WEIGHT | L'OREAL (FR) | 2002-10-08 | — | — | US | claimed |
| EP-1025898-B1 | Nanoemulsion from alkoxylated alkenyl succinates or alkoxylated alkenyl succinates of glucose and its cosmetic, dermatologic, ophtalmologic and/or pharmaceutical uses | OREAL (FR) | 2002-01-23 | — | — | EP | claimed |
| US-20010051170-A1 | Use of compounds which make it possible to modify the physicochemical properties of the skin and/or the mucous membranes as agents preventing or reducing the adhesion of microorganisms to the latter | L'OREAL (FR) | 2001-12-13 | — | — | US | claimed |
| EP-1129694-A1 | Use of components for modifying physico-chemical properties of the skin and/or the mucosal tissue as adhesion prevention/decreasing adhesion agents for microorganisms | L'OREAL (FR) | 2001-09-05 | — | — | EP | claimed |
| EP-1025898-A1 | Nanoemulsion from alkoxylated alkenyl succinates or alkoxylated alkenyl succinates of glucose and its cosmetic, dermatologic, ophtalmologic and/or pharmaceutical uses | L'OREAL (FR) | 2000-08-09 | — | — | EP | claimed |
| EP-0550879-B1 | Process for coating cellulosic membranes | AKZO NOBEL NV (NL) | 1997-03-12 | — | — | EP | claimed |
| US-12582715-B1 | Cancer radiation therapy with biocompatible quantum dots for simultaneous dose enhancement and counter-metastasis | CREIGHTON UNIVERSITY (US) | 2026-03-24 | — | — | US | disclosed |
| US-12516260-B2 | Fuel compositions | SHELL USA, INC. (US) | 2026-01-06 | — | — | US | disclosed |
| US-20250042940-A1 | 14-3-3 TARGETING PEPTIDES FOR CANCER TREATMENT | CREIGHTON UNIV (US) | 2025-02-06 | — | — | US | disclosed |
| EP-0070191-B2 | DETERGENT ADDITIVES AND DETERGENT COMPOSITIONS CONTAINING THEM | UNILEVER PLC (GB) | 1990-05-09 | — | — | EP | disclosed |
| US-4611087-A | (METH)ACRYLIC ESTERS; (METH)ALLYL ESTERS; REACTIVE SURFACTANTS | KAO CORPORATION (JP) | 1986-09-09 | — | — | US | disclosed |
| EP-0070191-B1 | DETERGENT ADDITIVES AND DETERGENT COMPOSITIONS CONTAINING THEM | UNILEVER PLC (GB) | 1985-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12582715-B1 | Cancer radiation therapy with biocompatible quantum dots for simultaneous dose enhancement and counter-metastasis | EPCAM, ROS1, DCX | PPARG 3591/4885PPARD 3786/4885PPARA 4570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.